Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

4247

Shown on this page

Local exact-city summaries

4247

Based on exact city/state matches in the local index.

Local exact-city recruiting

767

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for San Antonio, Texas. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 4,247 matching trials in San Antonio, TX.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for San Antonio, TX. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Diabetes Mellitus, Type 2 146 Breast Cancer 120 Prostate Cancer 73 Diabetes 70 Ovarian Cancer 68 Advanced Solid Tumor 66

Top sponsors in local exact-city summaries

The University of Texas Health Science Center at San Antonio 225 Children's Oncology Group 174 Pfizer 148 Eli Lilly and Company 139 National Cancer Institute (NCI) 132 Novo Nordisk A/S 118

Top therapies in local exact-city summaries

Cyclophosphamide 81 Pembrolizumab 77 Carboplatin 65 cyclophosphamide 57 Paclitaxel 49 Cisplatin 48

Indexed official records

Open in full search

Conditions: Castration-resistant Prostate Cancer (CRPC), ER+, HER 2- Breast Cancer, Microsatellite Stable (MSS) Colorectal Carcinoma, Non-small Cell Lung Cancer (NSCLC)
Interventions: Fulvestrant injection, IDE574; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: East Brunswick, New Jersey • Lake Success, New York • Austin, Texas + 6 more

Conditions: Acute Stroke, Ischemic Stroke
Interventions: Zoom System; Device
Lead sponsor: Imperative Care, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: Huntsville, Alabama • Walnut Creek, California • Tampa, Florida + 7 more

Conditions: Moderate Hepatic Impairment
Interventions: Capivasertib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Rialto, California • San Antonio, Texas

Conditions: Colitis, Ulcerative
Interventions: High-dose MH002, Low-dose MH002, Placebo; Drug
Lead sponsor: MRM Health NV; Industry
Eligibility: 16 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Miami, Florida • Palmetto Bay, Florida • Fayetteville, North Carolina + 2 more

Conditions: Diabetic Kidney Disease (DKD)
Interventions: ALN-ANG3, ALN-ANG3 placebo, Evinacumab, Evinacumab placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 51
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 42 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Breast Cancer
Interventions: Moderately Hypofractionated Radiation, Ultrahypofractionated Radiation; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Loveland, Colorado • Voorhees Township, New Jersey • Houston, Texas + 1 more

Conditions: FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation, Low-grade NMIBC
Interventions: TYRA-300 50mg, TYRA-300 60mg, TYRA-300 Dose TBD; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 25 more

Conditions: Castration-resistant Prostate Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Interventions: DCC-2812; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee + 2 more

Conditions: Crohn's Disease, Obesity or Overweight
Interventions: Mirikizumab, Placebo, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 35
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more

Conditions: Follicular Lymphoma
Interventions: Bendamustine, Cyclophosphamide, Doxorubicin, Golcadomide, Lenalidomide, Prednisone/Prednisolone, Rituximab, Vincristine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 31
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 25 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: Enzalutamide, PF-06821497, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 44
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 29 more

Clinical trials in San Antonio, Texas

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Continuous Dual Aspiration Technique With Zoom System for Stroke

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Confirmatory Clinical Study in Active Ulcerative Colitis

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Study of COYA 302 for the Treatment of ALS

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.